\n- Glofitamab pivotal Ph1b data in 3L+DLBCL \n- Polivy Asian sub-population data from Ph3 POLARIX in 1L DLBCL","Ginna Laporte, MD VP, Global Head Lymphoma/CLL Clinical Development"],["Oncology early R&D update","Johanna Bendell, M.D., Head of Roche Pharma Research and Early Development (pRED) Oncology \nAndy Chan, M.D., Ph.D. Senior Vice President, Research Biology, Genentech Research & Early Development (gRED)"],["Q&A",""]]" slot="left" uid="80e105b2-74f7-4f67-a105-0c892f2b2fd7" id="80e105b2-74f7-4f67-a105-0c892f2b2fd7" storyid="142243294" class="sc-roche-responsive-table-h hydrated">